Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring
Annals of hematology(2023)
Abstract
The incorporation of pediatric-inspired regimens in the adolescent-young-adult (AYA) and adult populations have resulted improved survival outcomes (Stock et al. Blood 133(14):1548–1559 2019 ; Dunsmore et al. J Clin Oncol 38(28):3282–3293 2020 ; DeAngelo et al. Leukemia 29(3):526-534 2015 ). Nonetheless incorporation of such regimens is limited by increased toxicity to asparaginase. Dosing strategies that reduce the weight-based dose of pegylated-L-asparaginase (PEG-asparaginase) utilizing activity monitoring have been shown to result in better tolerability of these regimens. The purpose of this study was to analyze the efficacy and safety of treating adults with Philadelphia chromosome negative (Ph−) ALL with pediatric-inspired regimens that incorporate PEG-asparaginase dose adjustments and asparaginase activity level monitoring. Patients aged 18–65 years initiated on pediatric-inspired regimens utilizing dose-reduced PEG-asparaginase with therapeutic drug monitoring-guided adjustments were included. The screening of 122 patients treated between 2015 and 2021 resulted in the inclusion of 54 patients. The median age of the cohort was 35 years (16–65 years), and median body mass index (BMI) was 30 kg/m 2 (18.3–53.4 kg/m 2 ). The 36-month survival estimate was 62.1% (95% CI 48.1–77.7%), and the median overall survival (OS) was 62.2 months (95% CI 35.1–89.3 months). In the AYA cohort, the 36-month survival was 71.2% (95% CI 55.8–91%) and the median overall survival was not reached. Survival was not significantly affected by immunophenotype or BMI. Discontinuation due to toxicity or hypersensitivity reactions was low at 11% and 9% respectively. The encouraging survival outcomes and favorable tolerability of this older population in the real-world setting support the use of individualized PEG-asparaginase dosing with PharmD-guided therapeutic drug monitoring.
MoreTranslated text
Key words
Acute lymphoblastic leukemia,Pediatric-inspired therapy,Asparaginase,Pegasparaginase,Therapeutic drug monitoring
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined